Abstract 115P
Background
Colorectal cancer is in fourth place due to mortality worldwide. In order to improve the diagnosis of colorectal cancer, immunohistochemical studies are becoming increasingly popular. The available literature contains a number of publications devoted to the study of the prognostic value of the expression of various biomarkers. However, the value of expression levels of the proliferation marker Ki-67 in colorectal cancer remains poorly understood. In this regard, the purpose of our study was to study the clinical significance of the expression of Ki-67 as a prognostic factor in patients with colorectal cancer.
Methods
To study the clinical significance of the expression of Ki-67 as a prognostic factor in patients with colorectal cancer, we examined 201 patients with colorectal cancer who were undergoing surgical treatment in combination with chemotherapy.
Results
A study of the proliferative activity of tumor glandular epithelial cells using patient Ki-67 proliferation marker showed that low or medium expression level (≤ 30%) was observed in 138 (68.9%) patients, while high (> 30%) - in 63 patients (31.1%). Binary logistic regression made it possible to establish links between the expression level of Ki-67 and the tumor stage, the presence of metastases in regional lymph nodes, the presence of distant metastases and the degree of tumor differentiation. In particular, patients with stage II, III, and IV stages of cancer had a higher chance of having a high level of Ki-67 expression than patients with stage I disease — 2.63, 3.16, and 3.97 times, respectively. The presence of 4 or more regional lymph nodes (N2) was accompanied by higher chances (6.6 times) to have a high level of expression of Ki-67, and the presence of distant metastases (M1) - by 1.92 times. Patients with low-differentiated cancer had a 5.1- times higher chance of being in the group with a high level of Ki-67 expression than patients with highly differentiated cancer.
Conclusions
The results of the research on finding the most informative and effective methods for predicting and diagnosing colorectal cancer among residents of the studied region will allow developing and introducing methods for complex primary and secondary prevention.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract